AzTrials
AzTrials

Nasopharyngeal CarcinomaPhase 2NCT03267498

Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC)

A Phase 2 study testing Nivolumab, Cisplatin and Radiation Therapy in people with Nasopharyngeal Carcinoma, run by Sue Yom at 2 sites in 2 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This phase II trial studies how well nivolumab and chemoradiotherapy works in treating patients with stage II-IVB nasopharyngeal cancer. Monoclonal antibodies, such as nivolumab, may block tumor growth in different ways by targeting certain cells. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Nasopharyngeal Carcinoma
What is being tested?
Nivolumab, Cisplatin and Radiation Therapy
Could I receive a placebo?
No, everyone receives an active treatment
How many people
40 participants
Where
2 sitesin 2 countries
Study dates
14 Feb 2018to 31 Oct 2024
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Males and females ≥18 years of age.
  • Histologically or cytologically confirmed nasopharyngeal carcinoma, stage II-IV by American Joint Committee on Cancer (AJCC) 7th edition, endemic-type (defined as World Health Organization (WHO) type 2a and 2b nonkeratinizing or undifferentiated subtypes, excluding WHO type I keratinizing subtype) performed on a biopsy that occurred within 90 days of registration.
  • Positron emission tomography-computed tomography (PET-CT) (preferred) or a CT of chest, abdomen, and pelvis within 60 days of registration showing radiographic stage II to IVB nasopharyngeal cancer.
  • No distant metastasis as verified by one of the study investigators.
  • Documentation that the patient is a candidate for chemoradiation of their nasopharyngeal cancer by one of the study investigators.
  • Ability to tolerate radiation therapy (e.g. lie flat and hold position for treatment).
Show all 26Show fewer
  • Measurable disease as defined by RECIST v1.1.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
  • Lack of contraindications to systemic immunotherapy (see list of exclusions below).
  • Resolution of all acute toxic effects of any prior chemotherapy, radiotherapy or surgical procedures to NCI CTCAE Version 5.0 grade 1.
  • Adequate hepatic, hematologic, and renal indices permitting administration of cisplatin and nivolumab (within 14 days of registration):
  • Hepatic Function:
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × upper limit of normal (ULN); Total bilirubin ≤ 1.5 × ULN (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL)
  • Adequate bone marrow function:
  • White blood cells (WBC) ≥ 2000/μL Neutrophils ≥ 1500/μL Platelet ≥ 100 x103/μL Hemoglobin > 9.0 g/dL
  • Adequate renal function:
  • Serum creatinine ≤ 1.5 × upper limit of normal (ULN) OR
  • Creatinine clearance (CrCl) > 40 mL/min (or > 50 mL/min for Singapore sites only) (if using the Cockcroft-Gault formula below):
  • Female CrCl = (140 - age in years) x weight in kg x 0.85 72 x serum creatinine in mg/dL Male CrCl = (140 - age in years) x weight in kg x 1.00 72 x serum creatinine in mg/dL
  • Women of childbearing potential must have a negative serum pregnancy test within 24 hours prior to the first dose of study treatment and agree to use appropriate highly effective methods of contraception, during the study and for 5 months following completion of study treatment; A "Woman of childbearing potential" is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. In addition, women under the age of 62 must have a documented serum follicle stimulating hormone (FSH) level less than 40 milli-international units per milliliter (mIU/mL).
  • Female Subjects:
  • Women of child bearing potential are expected to use one of the highly effective methods of contraception listed in the protocol.
  • Male Subjects:
  • Male subjects must inform their female partners who are women of child bearing potential of the contraceptive requirements and are expected to adhere to using contraception with their partner. Female partners of male subjects, who are women of child bearing potential, are expected to use one of the highly effective methods of contraception listed in the protocol. In addition, male subjects are expected to use a condom as noted in the protocol.
  • Men with a female partner of childbearing potential must agree to use highly effective methods of contraception or any contraceptive method with a failure rate of less than 1% per year during the study and for 7 months following completion of study treatment.
  • Ability to sign informed consent.

Who cannot join

  • Active second malignancy, i.e. patient known to have potentially fatal hematologic malignancy or another solid primary tumor present for which he/she may be (but not necessarily) currently receiving treatment. Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are allowed to enroll in this trial. For example, patients with early-stage skin cancers, prostate cancer under surveillance with non-rising prostate-specific antigen (PSA), or meningioma or thyroid papillary cancers which are under surveillance are eligible. For determinations of a specific clinical condition, please consult with the Principal Investigator.
  • Active, untreated central nervous system (CNS) metastases;
  • Prior treatment with any other anti-programmed cell death protein-1 (anti-PD-1), or PD Ligand-1 (PD-L1) or PD Ligand-2 (PD-L2), anti-cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways, or cancer vaccine;
  • Prior systemic cytotoxic therapy, antineoplastic biologic therapy, or major surgery within 28 days of first dose of study medication;
  • Severe hypersensitivity reaction to treatment during prior administration of a monoclonal antibody (mAb) or history of allergy to any study drug component;
  • Has received a live-virus vaccination within 30 days of planned treatment start;
Show all 23Show fewer
  • Condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
  • Any evidence of current interstitial lung disease (ILD) or pneumonitis or a prior history of ILD or pneumonitis requiring oral or IV glucocorticoids;
  • Active, known, or suspected autoimmune disease or any autoimmune condition that has required systemic treatment in the past 2 years (replacement therapies for hormone deficiencies are allowed); Subjects are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger.
  • Clinically active diverticulitis, intra-abdominal abscess, gastrointestinal (GI) obstruction, or abdominal carcinomatosis (known risks factors for bowel perforation);
  • Signs or symptoms of infection within 2 weeks prior to first day of study treatment.
  • Patients with active tuberculosis (clinical evaluation in line with local practice), or a known history of active tuberculosis that in the opinion of the treating investigator has a high risk of reactivation.
  • Received therapeutic oral or IV antibiotics within 2 weeks prior to first day of study treatment: Patients receiving prophylactic antibiotics (eg, to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible.
  • Known positive test for human immunodeficiency virus (HIV);
  • Known active hepatitis B or hepatitis C virus (HBV or HCV): Patients with past or resolved HBV infection (defined by a negative hepatitis B surface antigen (HBsAg) test and a positive anti-hepatitis B core antigen (HBc) (anti-HBc)antibody test) are eligible. HBV DNA must be obtained in these patients prior to first day of study treatment. Patients who have been recently discovered to have HBV with positive HBsAg test and positive anti-HBc antibody test but who have been started on antiretroviral treatment with nondetectable HBV DNA are eligible. HBV DNA must be obtained in these patients prior to first day of study treatment
  • Patients with known active hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection: Patients positive for HCV antibody are eligible only if Polymerase chain reaction (PCR) test is negative for HCV RNA.
  • Prior radiation therapy of any type within 7 days of first dose of study medication;
  • Prior radiation therapy to head and neck region that would overlap with intended radiation treatment for nasopharyngeal carcinoma;
  • Medical contraindication to radiation treatment (e.g. active systemic sclerosis, other uncontrolled autoimmune condition)
  • Treatment with prohibited medications (including concurrent anticancer therapy including chemotherapy, radiation, hormonal treatment [except corticosteroids and megestrol acetate] ≤ 14 days prior to treatment.
  • Pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study;
  • Active, uncontrolled psychiatric disorders or substance (drug/alcohol) abuse that interfere with patient's safety, ability to provide informed consent, or ability to comply with the protocol.
  • Persons who are incarcerated or otherwise under compulsory detention by an authority are not eligible.

Trial locations and contacts

2 sites in 2 countries.

2 sites in 2 countries

United States1 site

  • University of California, San Francisco

    San Francisco, California, 94143

Other trials in United States

Singapore1 site

  • National University Hospital Singapore

    Singapore, 119074

Other trials in Singapore

About this study

Official title: Nivolumab in Combination With Chemoradiation for Patients With Stage II-IVB Nasopharyngeal Carcinoma, A Phase II Study With Correlative Biomarkers

This phase II trial studies how well nivolumab and chemoradiotherapy works in treating patients with stage II-IVB nasopharyngeal cancer. Monoclonal antibodies, such as nivolumab, may block tumor growth in different ways by targeting certain cells. Chemoradiotherapy is the combination of chemotherapy and radiation therapy and may prevent the cancer from spreading when combined with nivolumab. Giving nivolumab and chemoradiotherapy may work better in treating patients with stage II-IVB nasopharyngeal cancer.

Read the detailed description

PRIMARY OBJECTIVES:

  1. To establish the feasibility of treatment completion of a combined chemoradiation-nivolumab regimen followed by adjuvant nivolumab.

SECONDARY OBJECTIVES:

  1. To determine the overall response rate at 1 year from end of treatment, as determined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.

II. To determine the locoregional control rate at 1 year post-treatment.

III. To determine the distant metastasis rate at 1 year post-treatment.

IV. To determine the rate of Epstein-Barr virus (EBV) deoxyribonucleic acid (DNA) clearance at end of chemoradiation and at 1 year from end of treatment.

  1. To determine the acute and late toxicity rates according to Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 5, including immune-related adverse events (AEs).

VI. To assess patients' quality of life from baseline through 1 year from end of treatment.

EXPLORATORY OBJECTIVES:

  1. To determine the overall survival rate at 5-year post-treatment.

II. To determine whether programmed death-ligand 1 (PD-L1) -positive immunohistochemistry and novel quantitative assays correlate to clinical outcome.

III. To determine if the density of infiltrating Cluster of differentiation 3 (CD3)+ T cells/μm2 correlates to clinical outcome.

IV. To monitor immune changes by flow cytometry in the circulating T cell response to EBV antigens.

  1. To compare the change in the circulating T-cell repertoire by TCR sequencing and single-cell T-cell profiling.

VI. To quantify treatment-induced changes over time in the circulating T cell immune response to EBV using T-cell receptor (TCR) sequencing and enzyme-linked immunospot (ELISPOT) assays.

OUTLINE:

Patients receive nivolumab intravenously (IV) over 60 minutes on day 1 of courses 1-5 and 7-12. Treatment repeats every 14 days for 11 courses in the absence of disease progression or unacceptable toxicity. Beginning at course 2, patients undergo radiation therapy once daily (QD) 5 days per week and receive cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 7 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 1, 3, 6, 9, and 12 months for up to 1 year and then survival follow-up information may be collected via telephone calls, clinic follow-up visits, or medical records review for up to an additional 4 years. Survival and disease status will be collected until participant death, withdrawal, or if the participant is lost to follow-up.

Being tested
Nivolumab, Cisplatin, Radiation Therapy
Medical subject headings
Nasopharyngeal Carcinoma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • NivolumabDrug

    Also called Opdivo

    Dosage 240mg of Nivolumab will be given intravenously over 60 minutes, every 14 days.

  • CisplatinDrug

    Dosage 40 mg/m2 of cisplatin will be given intravenously over 30-60 minutes, every 7 days.

  • Radiation TherapyRadiation

    2.12 Gy/fraction x 33 fractions of radiation therapy will be given, daily Monday - Friday

Study groups in NCT03267498
Study groupRoleWhat they receive
Nivolumab + chemoradiationExperimentalPatients receive nivolumab IV over 60 minutes on day 1 of courses 1-5 and 7-12. Treatment repeats every 14 days for 11 courses in the absence of disease progression or unacceptable toxicity. Beginning at course 2, patients undergo radiation therapy QD 5 days per week and receive cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 7 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
Receives: Drug: Nivolumab; Drug: Cisplatin; Radiation: Radiation Therapy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Rate of Completion of All Adjuvant Immunotherapy

    The rate of completion of all adjuvant therapy by patients treated at the maximum tolerated dose (MTD) schedule will be determined and compared to a historical control rate of 52%, the rate of completion of a standard adjuvant cisplatin-based platform to determine feasibility of study treatment

    Measured: Up to 1 year

Secondary outcomes (7)

  1. Overall Response Rate (ORR)

    The ORR is based on the best overall response (BOR) recorded from the first day of treatment until time of assessment. The percentages of patients with a best overall response rate of complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD) will be determined as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.

    Measured: Up to 1 year after completion of treatment

  2. Number of Treatment-related Adverse Events (AEs)

    Adverse events will be classified using the National Cancer Institute Common Toxicity Criteria (NCI-CTCAE) version 5.0 by the investigator assessment and reported by frequency of Adverse Events (AEs) attributed as definitely, probably, or possibly related to the study interventions.

    Measured: Up to 1 year after completion of treatment

  3. Mean Loco-regional Control (LRC) Rate

    Duration of LRC will be calculated as 1+ the number of days from the first day of treatment to time of documented locoregional clinical or radiographic relapse, progression or death due to any cause. For patients who continue treatment post-progression, the date of clinical or radiographic relapse or progression will be used for analysis. The Kaplan-Meier analysis will be used to calculate the mean LRC rate with full range.

    Measured: Up to 1 year after completion of treatment

  4. Mean Distant Metastasis (DM) Rate

    Time to DM will be calculated as 1+ the number of days from the first day of treatment to documented clinical or radiographic progression at a distant metastatic site, or death due to any cause. Pathologic confirmation is not required to document the date of distant progression. For patients who continue treatment post-progression, the date of clinical or radiographic progression will be used for analysis. The Kaplan-Meier analysis will be used to calculate the mean DM rate with full range.

    Measured: Up to 1 year after completion of treatment

  5. Mean Change in Scores on the Functional Assessment of Cancer Therapy - Nasopharyngeal Cancer (FACT-NP)

    The FACT-NP is a self-report instrument that measures multidimensional quality of life (QOL) in patients with Nasopharyngeal cancer-specific scale. The FACT-NP consists of 43 questions that address physical, social, emotional, and functional well-being, with additional specific questions relevant to persons with nasopharyngeal cancers. Each item has a score range of 0 (Not at all) to 4 (Very much). For the 37 general health and head and neck cancer sections, the raw score range is 0-148, with the higher scores indicating better QOL reported by the participant. The 6 remaining questions for the nasopharyngeal cancers also fall on the same range of 0 to 4, with a raw total score range of 0-24, but on this subscale, lower scores indicate a higher QOL.

    Measured: Up to 1 year after completion of treatment

  6. Percentage of Participants With Acute Toxicities

    Acute toxicity rates will be reported and classified according to CTCAE version 5 and include immune-related AEs

    Measured: Up to 1 year after completion of treatment

  7. Percentage of Participants With Late Toxicities

    Late toxicity rates will be reported and classified according to CTCAE version 5 and include immune-related AEs

    Measured: Up to 1 year after completion of treatment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Aug 2017
  2. Study start14 Feb 2018
  3. Primary completion31 Oct 2024
  4. Study completion31 Oct 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
Single-arm, open label clinical trial of concurrent and adjuvant nivolumab, including a run-in phase to establish basic feasibility of the nivolumab schedule followed by expansion.
Masking
None (open label)
Enrolment
40 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03267498
Sponsor's protocol ID
162010
Other IDs
NCI-2017-02291
Status last verified
Jan 2026
First submitted
23 Aug 2017
Last updated
12 Jan 2026
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Nivolumab, Cisplatin and Radiation Therapy in people with Nasopharyngeal Carcinoma, run by Sue Yom at 2 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 26 inclusion and 23 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 12 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States, Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 12 Jan 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Rate of Completion of All Adjuvant Immunotherapy (time frame: Up to 1 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03267498.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jan 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in